{"id":1687,"date":"2014-03-12T16:45:13","date_gmt":"2014-03-12T16:45:13","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=1687"},"modified":"2014-03-14T07:10:50","modified_gmt":"2014-03-14T07:10:50","slug":"intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/","title":{"rendered":"Intensivere Di\u00e4tberatung bei Patienten mit fr\u00fchem Diabetes mellitus Typ 2. Die Early ACTID-Studie"},"content":{"rendered":"<p>AMB 2011, 45, 70b &nbsp; Intensivere Di\u00e4tberatung bei Patienten mit fr\u00fchem Diabetes mellitus Typ 2. Die Early ACTID-Studie &nbsp; Diabetes mellitus Typ\u00a02 gilt als eine Wohlstandserkrankung. Diese sind charakterisiert durch \u00fcberm\u00e4\u00dfige Nahrungszufuhr und geringe k\u00f6rperliche Aktivit\u00e4t. Behandlungsleitlinien greifen diesen Umstand auf und empfehlen als ersten therapeutischen Schritt eine Di\u00e4t und vermehrte k\u00f6rperliche Aktivit\u00e4t. Erst nach [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2011, 45, 70b &nbsp; Intensivere Di\u00e4tberatung bei Patienten mit fr\u00fchem Diabetes mellitus Typ 2. Die Early ACTID-Studie &nbsp; Diabetes mellitus Typ\u00a02 gilt als eine Wohlstandserkrankung. Diese sind charakterisiert durch \u00fcberm\u00e4\u00dfige Nahrungszufuhr und geringe k\u00f6rperliche Aktivit\u00e4t. Behandlungsleitlinien greifen diesen Umstand auf und empfehlen als ersten therapeutischen Schritt eine Di\u00e4t und vermehrte k\u00f6rperliche Aktivit\u00e4t. Erst nach [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[199,844],"tags":[160,846,812],"class_list":["post-1687","post","type-post","status-publish","format-standard","hentry","category-jahr-2011-band-45","category-monat-9-jahr-2011-band-45","tag-diabetes-mellitus-typ-2","tag-early-actid-studie","tag-haemoglobin-hba1c"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Intensivere Di\u00e4tberatung bei Patienten mit fr\u00fchem Diabetes mellitus Typ 2. Die Early ACTID-Studie<\/title>\n<meta name=\"description\" content=\"Intensive Di\u00e4tberatung senkt in der Fr\u00fchphase des ...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intensivere Di\u00e4tberatung bei Patienten mit fr\u00fchem Diabetes mellitus Typ 2. Die Early ACTID-Studie\" \/>\n<meta property=\"og:description\" content=\"Intensive Di\u00e4tberatung senkt in der Fr\u00fchphase des ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2014-03-12T16:45:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-03-14T07:10:50+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Intensivere Di\u00e4tberatung bei Patienten mit fr\u00fchem Diabetes mellitus Typ 2. Die Early ACTID-Studie\",\"datePublished\":\"2014-03-12T16:45:13+00:00\",\"dateModified\":\"2014-03-14T07:10:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\\\/\"},\"wordCount\":648,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"keywords\":[\"Diabetes mellitus Typ 2\",\"Early ACTID-Studie\",\"H\u00e4moglobin HbA1C\"],\"articleSection\":[\"Jahr 2011 Band 45\",\"Monat 9\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\\\/\",\"name\":\"Intensivere Di\u00e4tberatung bei Patienten mit fr\u00fchem Diabetes mellitus Typ 2. Die Early ACTID-Studie\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"datePublished\":\"2014-03-12T16:45:13+00:00\",\"dateModified\":\"2014-03-14T07:10:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"Intensive Di\u00e4tberatung senkt in der Fr\u00fchphase des ...\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intensivere Di\u00e4tberatung bei Patienten mit fr\u00fchem Diabetes mellitus Typ 2. Die Early ACTID-Studie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intensivere Di\u00e4tberatung bei Patienten mit fr\u00fchem Diabetes mellitus Typ 2. Die Early ACTID-Studie","description":"Intensive Di\u00e4tberatung senkt in der Fr\u00fchphase des ...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/","og_locale":"de_DE","og_type":"article","og_title":"Intensivere Di\u00e4tberatung bei Patienten mit fr\u00fchem Diabetes mellitus Typ 2. Die Early ACTID-Studie","og_description":"Intensive Di\u00e4tberatung senkt in der Fr\u00fchphase des ...","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2014-03-12T16:45:13+00:00","article_modified_time":"2014-03-14T07:10:50+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Intensivere Di\u00e4tberatung bei Patienten mit fr\u00fchem Diabetes mellitus Typ 2. Die Early ACTID-Studie","datePublished":"2014-03-12T16:45:13+00:00","dateModified":"2014-03-14T07:10:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/"},"wordCount":648,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","keywords":["Diabetes mellitus Typ 2","Early ACTID-Studie","H\u00e4moglobin HbA1C"],"articleSection":["Jahr 2011 Band 45","Monat 9"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/","name":"Intensivere Di\u00e4tberatung bei Patienten mit fr\u00fchem Diabetes mellitus Typ 2. Die Early ACTID-Studie","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","datePublished":"2014-03-12T16:45:13+00:00","dateModified":"2014-03-14T07:10:50+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"Intensive Di\u00e4tberatung senkt in der Fr\u00fchphase des ...","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intensivere-diaetberatung-bei-patienten-mit-fruehem-diabetes-mellitus-typ-2-die-early-actid-studie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Intensivere Di\u00e4tberatung bei Patienten mit fr\u00fchem Diabetes mellitus Typ 2. Die Early ACTID-Studie"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=1687"}],"version-history":[{"count":2,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1687\/revisions"}],"predecessor-version":[{"id":1718,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1687\/revisions\/1718"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=1687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=1687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=1687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}